Kobby Asubonteng

461 total citations
11 papers, 131 citations indexed

About

Kobby Asubonteng is a scholar working on Oncology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Kobby Asubonteng has authored 11 papers receiving a total of 131 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Psychiatry and Mental health and 2 papers in Molecular Biology. Recurrent topics in Kobby Asubonteng's work include Attention Deficit Hyperactivity Disorder (3 papers), Acute Myeloid Leukemia Research (2 papers) and Statistical Distribution Estimation and Applications (2 papers). Kobby Asubonteng is often cited by papers focused on Attention Deficit Hyperactivity Disorder (3 papers), Acute Myeloid Leukemia Research (2 papers) and Statistical Distribution Estimation and Applications (2 papers). Kobby Asubonteng collaborates with scholars based in United States, Canada and France. Kobby Asubonteng's co-authors include Govind S. Mudholkar, Tara L. Lin, Alan D. Hutson, Stefan Faderl, Jörge E. Cortes, Thomas Prébet, Jeffrey E. Lancet, Do‐Youn Oh, J. Armstrong and Filip De Vos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Kobby Asubonteng

9 papers receiving 129 citations

Peers

Countries citing papers authored by Kobby Asubonteng

Since Specialization

Citations

This map shows the geographic impact of Kobby Asubonteng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kobby Asubonteng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kobby Asubonteng more than expected).

Fields of papers citing papers by Kobby Asubonteng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kobby Asubonteng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kobby Asubonteng. The network helps show where Kobby Asubonteng may publish in the future.

Co-authorship network of co-authors of Kobby Asubonteng

This figure shows the co-authorship network connecting the top 25 collaborators of Kobby Asubonteng. A scholar is included among the top collaborators of Kobby Asubonteng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kobby Asubonteng. Kobby Asubonteng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Viloxazine Extended-Release Administered With Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Phase 4, Open-Label Trial 2025 ·Journal of Child and Adolescent Psychopharmacology ·Ann Childress, Kobby Asubonteng, Gregory R. Cox, (unknown), (unknown), (unknown), Jonathan Rubin	1
2	An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder 2024 ·CNS Drugs ·Ann Childress, Andrew J. Cutler, Lenard A. Adler, (unknown), Kobby Asubonteng, (unknown), (unknown), Jonathan Rubin	1
3	Qelbree (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults with ADHD 2024 ·CNS Spectrums ·Ann Childress, Andrew J. Cutler, Lenard A. Adler, (unknown), Kobby Asubonteng, (unknown), Jonathan Rubin	1
4	Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial 2022 ·Journal of Hematology & Oncology ·Jörge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet, Thomas Prébet	24
5	Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide for the Treatment of Severe/Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation 2021 ·Blood ·Mohamad Mohty, Didier Blaise, Régis Peffault de Latour, Myriam Labopin, Marie Y. Detrait, Stéphane Girault, Anne Huynh, Hélène Labussière‐Wallet, Thierry Lamy, Delphine Lebon, Sébastien Maury, C. Rénard, Kobby Asubonteng, (unknown), Ibrahim Yakoub‐Agha, Jean‐Hugues Dalle	0
6	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy 2019 ·Clinical Cancer Research ·Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin, Do‐Youn Oh, Bhumsuk Keam, Hyo Jin Lee, (unknown), Ewa Kalinka‐Warzocha, Filip De Vos, (unknown), Salvatore Ferro, Feng Xiao, Paul Baverel, (unknown), Kobby Asubonteng, Nassim Morsli, Luc Dirix	34
7	Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study 2017 ·Annals of Oncology ·Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno, J. Good, Jérôme Fayette, Nathaniel Bouganim, Neal Ready, Paul Clement, (unknown), Anthony Jarkowski, J. Armstrong, Kobby Asubonteng, Giovanni Melillo, Ricard Mesı́a	24
8	Thick primary melanoma has a heterogeneous tumor biology: an institutional series 2011 ·World Journal of Surgical Oncology ·Ari‐Nareg Meguerditchian, Kobby Asubonteng, (unknown), (unknown), Gregory E. Wilding, John M. Kane	13
9	Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). 2011 ·Journal of Clinical Oncology ·Richard S. Finn, (unknown), Thomas Yau, (unknown), (unknown), Yibin Kang, (unknown), Carlos Gómez-Martín, Carlos Rodríguez de Lope, (unknown), Tanya Paquet, Kobby Asubonteng, Robert Winkler, Özlem Anak, Dalila Sellami, Jordi Bruix	17
10	Data-transformation approach to lifetimes data analysis: An overview 2010 ·Journal of Statistical Planning and Inference ·Govind S. Mudholkar, Kobby Asubonteng	5
11	Transformation of the bathtub failure rate data in reliability for using Weibull-model analysis 2009 ·Statistical Methodology ·Govind S. Mudholkar, Kobby Asubonteng, Alan D. Hutson	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact